P014 Final results of the SUCCESS Study: SUccess in Comaneci-assist Coils Embolization Surveillance Study

<h3>Introduction</h3> Comaneci is a retrievable coil assist device that is radially adjustable and designed as an adjunct without limiting blood flow. <h3>Aim of Study</h3> The objective of this FDA-regulated postmarket study is to assess the safety and performance of the device in US clinical practice. <h3>Methods</h3> SUCCESS is a multicenter, single arm, open, prospective study, enrolling 90 consecutive subjects in 17 US centers. Subjects must have a wide neck (4-10 mm or dome to neck ratio &lt;2) intracranial aneurysm, either ruptured or unruptured, that is suitable for coil embolization. Effectiveness endpoints include successful aneurysm occlusion at procedure and 6 months, and clinical outcome at 6 months. Safety endpoints include intraoperative complications. <h3>Results</h3> Subjects were enrolled between November 2020 and October 2023 (64% unruptured, 36% ruptured) Overall, a total of 356 coils were used in these cases. Successful Occlusion at end of procedure was 87.8% (N=90), and 81.7% at 6 month follow up (N=71), good clinical outcome (mRS 0-2) was 73% at baseline, 81% at 30 days and 86% at 6 months (P&lt;0.05). Major safety outcomes: Intraoperative thromboembolic events were reported in 5 subjects (5.5%), none were symptomatic; mortality 4.4%, all in ruptured cases; coil entanglement occurred for 1 coil out of the overall 392 coils (0.3%). <h3>Conclusion</h3> Interim data demonstrates a high rate of successful aneurysm occlusion when using Comaneci as an assist device in wide neck aneurysms. This effect is sustainable and is accompanied by an improvement in clinical outcome. Safety profile is favorable with low thromboembolic rates. <h3>Disclosure of Interest</h3> yes Hanel- Medtronic Consultant Stryker Consultant Cerenovous Consultant Microven4on Consultant Balt Consultant Phenox Consultant Rapid Medical Consultant Q’Apel Consultant MiVI Advisory Board eLum Advisory Board Three Rivers Medical Inc Advisory Board Shape Medical Advisory Board Corindus Advisory Board NIH Research Grant Interline Endowment Research Grant Microven4on Research Grant Stryker Research Grant CNX Research Grant InNeuroCo Investor/Stockholder Cerebrotech Investor/Stockholder eLum Investor/Stockholder Endostream Investor/Stockholder Three Rivers Medical Inc Investor/Stockholder Scien4a Investor/Stockholder RisT Investor/Stockholder BlinkTBI Investor/Stockholder Corindus Investor/Stockholder NTI Investor/Stockholder, Davies - Research Grants: NIH R21/R01, NSF SBIR, UB-CAT, Buffalo Translational Consortium, Cummings Foundation, nVidia, Google Financial Interest: QAS.ai, Rist Neurovascular, Cerebrotech, Synchron, Hyperion Consultant/Advisory Board: Medtronic, Microvention, Imperative Care, Xenter, RapidPulse, Canon, J&amp;J National PI/Steering Committees: StrokeNET DSMB, EMBOLISE, SUCCESS, RapidPulse, SBIR/STTR, NIH NINDS/NLM Study sections.

Authors

Institutions

Publication Details

Journal
Abstracts
Published
2024-09-01
DOI
https://doi.org/10.1136/jnis-2024-esmint.51
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P014 Final results of the SUCCESS Study: SUccess in Comaneci-assist Coils Embolization Surveillance Study

Ricardó A. Hanel, Jason M. Davies
1 links
Abstracts
Venous Thromboembolism Diagnosis and Management
article

P014 Final results of the SUCCESS Study: SUccess in Comaneci-assist Coils Embolization Surveillance Study

Ricardó A. Hanel, Jason M. Davies
article en

Abstract

<h3>Introduction</h3> Comaneci is a retrievable coil assist device that is radially adjustable and designed as an adjunct without limiting blood flow. <h3>Aim of Study</h3> The objective of this FDA-regulated postmarket study is to assess the safety and performance of the device in US clinical practice. <h3>Methods</h3> SUCCESS is a multicenter, single arm, open, prospective study, enrolling 90 consecutive subjects in 17 US centers. Subjects must have a wide neck (4-10 mm or dome to neck ratio &lt;2) intracranial aneurysm, either ruptured or unruptured, that is suitable for coil embolization. Effectiveness endpoints include successful aneurysm occlusion at procedure and 6 months, and clinical outcome at 6 months. Safety endpoints include intraoperative complications. <h3>Results</h3> Subjects were enrolled between November 2020 and October 2023 (64% unruptured, 36% ruptured) Overall, a total of 356 coils were used in these cases. Successful Occlusion at end of procedure was 87.8% (N=90), and 81.7% at 6 month follow up (N=71), good clinical outcome (mRS 0-2) was 73% at baseline, 81% at 30 days and 86% at 6 months (P&lt;0.05). Major safety outcomes: Intraoperative thromboembolic events were reported in 5 subjects (5.5%), none were symptomatic; mortality 4.4%, all in ruptured cases; coil entanglement occurred for 1 coil out of the overall 392 coils (0.3%). <h3>Conclusion</h3> Interim data demonstrates a high rate of successful aneurysm occlusion when using Comaneci as an assist device in wide neck aneurysms. This effect is sustainable and is accompanied by an improvement in clinical outcome. Safety profile is favorable with low thromboembolic rates. <h3>Disclosure of Interest</h3> yes Hanel- Medtronic Consultant Stryker Consultant Cerenovous Consultant Microven4on Consultant Balt Consultant Phenox Consultant Rapid Medical Consultant Q’Apel Consultant MiVI Advisory Board eLum Advisory Board Three Rivers Medical Inc Advisory Board Shape Medical Advisory Board Corindus Advisory Board NIH Research Grant Interline Endowment Research Grant Microven4on Research Grant Stryker Research Grant CNX Research Grant InNeuroCo Investor/Stockholder Cerebrotech Investor/Stockholder eLum Investor/Stockholder Endostream Investor/Stockholder Three Rivers Medical Inc Investor/Stockholder Scien4a Investor/Stockholder RisT Investor/Stockholder BlinkTBI Investor/Stockholder Corindus Investor/Stockholder NTI Investor/Stockholder, Davies - Research Grants: NIH R21/R01, NSF SBIR, UB-CAT, Buffalo Translational Consortium, Cummings Foundation, nVidia, Google Financial Interest: QAS.ai, Rist Neurovascular, Cerebrotech, Synchron, Hyperion Consultant/Advisory Board: Medtronic, Microvention, Imperative Care, Xenter, RapidPulse, Canon, J&amp;J National PI/Steering Committees: StrokeNET DSMB, EMBOLISE, SUCCESS, RapidPulse, SBIR/STTR, NIH NINDS/NLM Study sections.

Abstracts
Baptist Medical Center Jacksonville (US), University at Buffalo, State University of New York (US)
Zero hunger
Openalex Percentile: Top 71%
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.